We’ve rebranded some of our products, learn more ›

CODEX® is now PhenoCycler,
Phenoptics™ is now Phenolmager.

Spatial Phenotyping: A Revolutionary Approach to Biomarker Discovery for Cancer Immunotherapy

Webinar | Sep 14, 2023 | 8AM PT | 11 AM ET | 5PM CET

When we think of conducting spatial biology experiments, the technologies used must be capable of spatially resolved, highly multiplexed biomarker analysis. Single-cell technologies, such as flow cytometry and single-cell RNA-seq, can detect numerous parameters but lack spatial dimension. The advent of some recent spatial technologies has alleviated this concern, but spot-based or region-of-interest-based methods still lack resolution. Standard imaging methods, like immunofluorescence (IF) and immunohistochemistry (IHC) provide single-cell resolution and spatial context but are limited to measuring just a few parameters simultaneously. Akoya Biosciences PhenoCycler®-Fusion, offers a balance between resolution, cellular context, and ultrahigh-plex biomarker detection. Akoya’s integrated platform combines the strengths of the automated, ultrahigh multiplex cycling platform, PhenoCycler, and the high-speed imaging platform, PhenoImager, into an end-to-end, integrated workflow.

In this webinar, Dr. Arutha Kulasinghe, NHMRC Research Fellow and Clinical-oMx Group Leader at the Frazer Institute, University of Queensland, will discuss how single-cell spatial phenotyping is an invaluable tool when characterizing the tumor microenvironment and how this technology can be used to develop consistently predictive biomarkers for guiding patient selection for highly targeted therapy.

Key learning objectives

  • Understand spatial biology approaches
  • Learn how to profile deep tumor microenvironments
  • Understand how to decode immunotherapy responses
  • Discover applications for skin, lung and head, and neck cancer




Arutha Kulasinghe

Arutha Kulasinghe, PhD

NHMRC Research Fellow and Group Leader
University of Queensland

Arutha Kulasinghe is a Peter Doherty NHMRC Research Fellow and leads the 'Clinical-oMx Lab' at the University of Queensland. Kulasinghe has pioneered spatial transcriptomics using digital spatial profiling approaches in the Asia-Pacific region, contributing to world-first studies for lung cancer, head and neck cancer, and COVID-19. His research aims to understand the underlying pathobiology by using an integrative multi-omics approach. Kulasinghe has published his research in 60 manuscripts and is supported by the NHMRC, the Australian Academy of Sciences, Cancer Australia, Cure Cancer, MRFF, and numerous philanthropic and hospital foundations.